Antithrombotic therapy of pregnant women suffering from certain congenital cardiopathologies

The paper discusses the features of antithrombotic therapy of pregnant women suffering from congenital cardiopathologies. Providing medical care to women suffering from cardiovascular diseases and carrying a child is a difficult task due to the unique maternal physiology, which causes profound changes in many organ systems. First of all, such difficulties are caused by the presence of the fetus, since individual approaches to the treatment of cardiac diseases of the mother can have an adverse disease on the child. Conversely, the patient’s refusal of the necessary treatment due to potential harm to the fetus is fraught with a bad outcome for both the mother and the child. Physiological adaptation of the mother’s body during pregnancy can provoke cardiometabolic complications and cause thrombosis, the consequences of which can be fatal. Accordingly, the development of approaches to the organization of antithrombotic therapy of pregnant patients with cardiopathologies can contribute to improving the survival of the mother and fetus during pregnancy, as well as create prerequisites for a successful delivery and postpartum recovery of the woman and child.